glp 1 agonists anesthesia GLP-1 Receptor and Gastrointestinal Endoscopy: A Narrative Review of Risks, Management Strategies, and the Need for Clinical Consensus glp 1 agonists anesthesia Are
Description
31 dicembre 2016;2(1):1229086
21 Gastrointestinal adverse effects are dose dependent and reported as the reason for withdrawal of 36 liraglutide-treated subjects (5% of all liraglutide subjects)
Looking from 2023 to 2024, the latest year of data available, prescriptions and gross spending for Wegovy (first approved for obesity in 2021, approved for cardiovascular disease in 2024) and Mounjaro (approved for type 2 diabetes in 2022) more than doubled, and prescriptions and gross spending for Zepbound (first approved for obesity in 2023, approved for sleep apnea in 2024) increased more than fivefold
As a secondary end-point, a direct comparison with liraglutide (up to 1.8 mg) was made
Embrace small changes over timethese cumulative efforts can lead to significant improvements in managing weight effectively without relying solely on pharmaceutical aids like GLP-1 agonists
Alghamdi FA, Alshegifi HA, Alhuthayli RS, et al
